ESD for upper esophageal cancer

Endoscopic submucosal dissection (ESD) is increasingly recognized as an effective and minimally invasive treatment option for superficial esophageal squamous neoplasms (ESN), including early-stage esophageal cancer. This technique is particularly suitable for treating superficial lesions confined to the mucosal or submucosal layers of the esophagus, as it allows for precise removal of the tumor while preserving the surrounding esophageal tissue.

The procedure involves the use of specialized endoscopic tools to dissect and remove the cancerous lesion en bloc (in one piece), which ensures complete removal and allows for accurate pathological assessment. ESD is recommended as the standard of care for early esophageal squamous cell carcinoma (ESCC) when the lesion meets specific criteria for curative resection, such as limited depth of invasion, absence of lymphovascular invasion, and no evidence of lymph node metastasis.

Key benefits of ESD for upper esophageal cancer include high rates of complete tumor removal (en bloc and R0 resection), low recurrence rates in curative resections, and the ability to preserve the esophagus, thereby avoiding more invasive surgical procedures like esophagectomy. However, patient selection is critical to ensure optimal outcomes, as deeper or more advanced lesions may require additional treatments such as surgery or chemoradiotherapy.

The safety profile of ESD is generally favorable, with a low risk of complications such as bleeding or perforation, though these risks increase with larger or more complex lesions. In the Western world, data on ESD for esophageal cancer is still emerging, but studies indicate that it is a viable and effective treatment option, with outcomes comparable to those reported in Asian countries where the procedure is more established.

In summary, ESD represents a safe and effective approach for the treatment of upper esophageal cancer, particularly for superficial lesions. It offers the advantages of organ preservation, accurate pathological assessment, and low recurrence rates, making it a preferred option for carefully selected patients with early-stage esophageal cancer. However, long-term follow-up and multidisciplinary care are essential to monitor for recurrence or progression, especially in cases where curative resection criteria are not met.